BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 26175116)

  • 1. [(18)F]Florbetaben: a review in β-amyloid PET imaging in cognitive impairment.
    Syed YY; Deeks E
    CNS Drugs; 2015 Jul; 29(7):605-13. PubMed ID: 26175116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal assessment of cerebral β-amyloid deposition in mice overexpressing Swedish mutant β-amyloid precursor protein using 18F-florbetaben PET.
    Rominger A; Brendel M; Burgold S; Keppler K; Baumann K; Xiong G; Mille E; Gildehaus FJ; Carlsen J; Schlichtiger J; Niedermoser S; Wängler B; Cumming P; Steiner H; Herms J; Haass C; Bartenstein P
    J Nucl Med; 2013 Jul; 54(7):1127-34. PubMed ID: 23729696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.
    Barthel H; Luthardt J; Becker G; Patt M; Hammerstein E; Hartwig K; Eggers B; Sattler B; Schildan A; Hesse S; Meyer PM; Wolf H; Zimmermann T; Reischl J; Rohde B; Gertz HJ; Reininger C; Sabri O
    Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1702-14. PubMed ID: 21547601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Amyloid positron-emission-tomography with [
    Schönecker S; Prix C; Raiser T; Ackl N; Wlasich E; Stenglein-Krapf G; Mille E; Brendel M; Sabri O; Patt M; Barthel H; Bartenstein P; Levin J; Rominger A; Danek A
    Nervenarzt; 2017 Feb; 88(2):156-161. PubMed ID: 27913818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.
    Sabri O; Sabbagh MN; Seibyl J; Barthel H; Akatsu H; Ouchi Y; Senda K; Murayama S; Ishii K; Takao M; Beach TG; Rowe CC; Leverenz JB; Ghetti B; Ironside JW; Catafau AM; Stephens AW; Mueller A; Koglin N; Hoffmann A; Roth K; Reininger C; Schulz-Schaeffer WJ;
    Alzheimers Dement; 2015 Aug; 11(8):964-74. PubMed ID: 25824567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Tracer Retention Levels on Visual Analysis of Cerebral [
    Giovacchini G; Giovannini E; Borsò E; Lazzeri P; Duce V; Ferrando O; Foppiano F; Ciarmiello A
    Curr Radiopharm; 2021; 14(1):70-77. PubMed ID: 32727344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis.
    Heurling K; Leuzy A; Zimmer ER; Lubberink M; Nordberg A
    Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):362-373. PubMed ID: 26440450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Florbetaben to trace amyloid-β in the Alzheimer brain by means of PET.
    Barthel H; Sabri O
    J Alzheimers Dis; 2011; 26 Suppl 3():117-21. PubMed ID: 21971456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of early-phase [
    Daerr S; Brendel M; Zach C; Mille E; Schilling D; Zacherl MJ; Bürger K; Danek A; Pogarell O; Schildan A; Patt M; Barthel H; Sabri O; Bartenstein P; Rominger A
    Neuroimage Clin; 2017; 14():77-86. PubMed ID: 28138429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.
    Barthel H; Gertz HJ; Dresel S; Peters O; Bartenstein P; Buerger K; Hiemeyer F; Wittemer-Rump SM; Seibyl J; Reininger C; Sabri O;
    Lancet Neurol; 2011 May; 10(5):424-35. PubMed ID: 21481640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [
    Stenzel J; Rühlmann C; Lindner T; Polei S; Teipel S; Kurth J; Rominger A; Krause BJ; Vollmar B; Kuhla A
    Curr Alzheimer Res; 2019; 16(1):49-55. PubMed ID: 30345916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.
    Brendel M; Delker A; Rötzer C; Böning G; Carlsen J; Cyran C; Mille E; Gildehaus FJ; Cumming P; Baumann K; Steiner H; Haass C; Herms J; Bartenstein P; Rominger A
    Neuroimage; 2014 Jan; 84():843-53. PubMed ID: 24055703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
    Morris E; Chalkidou A; Hammers A; Peacock J; Summers J; Keevil S
    Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):374-385. PubMed ID: 26613792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of florbetaben PET imaging and the amyloid peptide Aß42 in cerebrospinal fluid.
    Schipke CG; Koglin N; Bullich S; Joachim LK; Haas B; Seibyl J; Barthel H; Sabri O; Peters O
    Psychiatry Res Neuroimaging; 2017 Jul; 265():98-101. PubMed ID: 28024844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid- and FDG-PET imaging in amyotrophic lateral sclerosis.
    Matías-Guiu JA; Pytel V; Cabrera-Martín MN; Galán L; Valles-Salgado M; Guerrero A; Moreno-Ramos T; Matías-Guiu J; Carreras JL
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2050-60. PubMed ID: 27262702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.
    Ikonomovic MD; Buckley CJ; Heurling K; Sherwin P; Jones PA; Zanette M; Mathis CA; Klunk WE; Chakrabarty A; Ironside J; Ismail A; Smith C; Thal DR; Beach TG; Farrar G; Smith AP
    Acta Neuropathol Commun; 2016 Dec; 4(1):130. PubMed ID: 27955679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval.
    Cortes-Blanco A; Prieto-Yerro C; Martinez-Lazaro R; Zamora J; Jiménez-Huete A; Haberkamp M; Pohly J; Enzmann H; Zinserling J; Strassmann V; Broich K
    Alzheimers Dement; 2014 Oct; 10(5 Suppl):S395-9. PubMed ID: 24418060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of brain beta-amyloid deposition in transgenic mouse models of Alzheimer's disease with PET imaging agents
    Son HJ; Jeong YJ; Yoon HJ; Lee SY; Choi GE; Park JA; Kim MH; Lee KC; Lee YJ; Kim MK; Cho K; Kang DY
    BMC Neurosci; 2018 Jul; 19(1):45. PubMed ID: 30053803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans.
    Rullmann M; Dukart J; Hoffmann KT; Luthardt J; Tiepolt S; Patt M; Gertz HJ; Schroeter ML; Seibyl J; Schulz-Schaeffer WJ; Sabri O; Barthel H
    J Nucl Med; 2016 Feb; 57(2):198-203. PubMed ID: 26541776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age dependence of brain β-amyloid deposition in Down syndrome: An [18F]florbetaben PET study.
    Jennings D; Seibyl J; Sabbagh M; Lai F; Hopkins W; Bullich S; Gimenez M; Reininger C; Putz B; Stephens A; Catafau AM; Marek K
    Neurology; 2015 Feb; 84(5):500-7. PubMed ID: 25568295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.